Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue

Cytokine

Volumn 8, Issue 8, 1996, Pages 658-666

  Darcissac, Edith C A ^a   Bahr, George M ^a   Pouillart, Philippe R ^a   Riveau, Gilles J ^c   Parant, Monique A ^b  

^a Vacsyn SA 33 bld du Gen M   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Cytokine; Human cells; Immunostimulation; Muramyl dipeptide

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; MURABUTIDE; MURAMYL DIPEPTIDE DERIVATIVE; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0030220753     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1996.0088     Document Type: Article

References (44)

1. 1. Tracey KJ, Cerami A (1993) Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 9:317-343.
2. 2. Ertel W, Kremer JP, Kenney J, Steckholzer U, Jarrar D, Trentz O, Schildberg FW (1995)Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85:1341-1347.
3. 3. Ralph P (1991) Negative regulation of cytokines - Inhibition of the production of IL1 and TNF, and a new form of the IL1 receptor antagonist. In Cellular and Cytokine Networks in Tissue Immunity, Wiley-Liss, Chichester, Inc. pp 15-29.
4. 4. Bogdan C, Nathan C (1993) Modulation of macrophage function by transforming growth factor ß, interleukin-4, and interleukin-10. Ann NY Acad Sci 685:713-739.
5. 5. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW (1994) Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 83:113-118.
6. 6. Thompson RC, Dripps DJ, Eisenberg SP (1991) IL-1ra: properties and uses of an interleukin-1 receptor antagonist. In Progress in Inflammation Research and Therapy. Birkhäuser Vergal, Basel, pp 41-49.
7. 7. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proc Natl A cad Sci USA 89:4845-4849.
8. 8. Chedid LA, Parant MA, Audibert FM, Riveau GJ, Parant FJ, Lederer E, Choay JP, Lefrancier PL (1982) Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun 35:417-424.
9. 9. Bahr GM, Darcissac E, Bevec D, Dukor P, Chedid L (1995) Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. Int J Immunopharmac 17:117-131.
10. 10. Parant M (1995) Muramyl dipeptides with special attention to TNF. In Stewart-Tull DES (eds) The Theory and Practical Application of Adjuvants. John Wiley & Sons Ltd, Chichester, pp 265-285.
11. 11. Granowitz EV, Porat R, Mier JW, Orencole SF, Callahan MV, Cannon JG, Lynch EA, Ye K, Poutsiaka DD, Vannier E, Shapiro L, Pribble JP, Stiles DM, Catalano MA, Wolff SM, Dinarello CA (1993) Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood 82:2985-2990.
12. 12. Sone S, Lopez-Berestein G, Fidler IJ (1986) Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives. Cancer Immunol Immunother 21:93-99.
13. 13. Vermeulen MW, David JR, Remold HG (1987) Differential mRNA responses in human macrophages activated by interferon-γ and muramyl dipeptide. J Immunol 139:7-9.
14. 14. DeForge LE, Remick DG (1991) Kinetics of TNF, IL-6, and IL-8 gene expression in LPS-stimulated human whole blood. Biochem Biophys Res Comm 174:18-24.
15. 15. Ulich TR, Del Castillo J, Busser K, Guo K, Yin S (1989) Acute in vivo effects of IL-3 alone and in combination with IL-6 on the blood cells of the circulation and bone marrow. Am J Pathol 135:663-670.
16. 16. Kishimoto T (1989) The biology of interleukin-6. Blood 74:1-10.
17. 17. Scarffe JH (1991) Emerging clinical uses for GM-CSF. Eur J Cancer 27:1493-1504.
18. 18. Foa R, Meloni G, Tosti S, Novarino A, Fenu S, Guarini A, Cardona S, Gillio Tos A, Gavosto F, Mandelli F (1990) Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological finding. Bone Marrow Transplant 6 [suppl.]: 98-102.
19. 19. Hirano T (1994) Interleukin-6. In Thomson W (ed) The Cytokine Handbook, 2nd Edn. pp 145-168.
20. 20. Metcalf D (1993) Hematopoietic regulators: redundancy or subtlety? Blood 82:3515-3523.
21. 21. Cluitmans FHM, Esendam BHJ, Landegent JE, Willemze R, Falkenburg JHF (1993) Regulatory effects of T cell lymphokines on cytokine gene expression in monocytes. Lymphokine and Cytokine Research 12:457-464.
22. 22. Bahr GM, Darcissac E, Pouillart PR, Chedid LA (1996) Synergistic effects between recombinant IL-2 and the synthetic immunomodulator murabutide: selective enhancement of cytokine release and potentiation of anti-tumor activity. J Interferon Cytokine Res 16:159-178.
23. 23. Takada H, Kotani S (1995) Muramyl dipeptide and derivatives. In Stewart-Tull DES (ed) The Theory and Practical Application of Adjuvants. John Wiley & Sons Ltd, Chichester, pp 171-202.
24. 24. Asano T, McWatters A, An T, Matsushima K, Kleinerman ES (1994) Liposomal muramyl tripeptide up-regulates interleukin-1α, interleukin-1β, tumor necrosis factor-α, interleukin-6 and interleukin-8 gene expression in human monocytes. J Pharmacol Exp Ther 268:1032-1039.
25. 25. Azuma I, Otani T (1995) An acyl-MDP derivative, MDP-Lys (L18) (Romurtide). In Stewart-Tull DES (ed) The Theory and Practical Application of Adjuvants. John Wiley & Sons Ltd, Chichester, pp 240-264.
26. 26. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA (1990) Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40-47.
27. 27. Kunkel SL, Lukacs NW, Strieter RM (1994) The role of interleukin-8 in the infectious process. Ann NY Acad Sci 730:134-143.
28. 28. Riveau GJ, Brunel-Riveau BG, Audibert FM, Chedid LA (1991) Influence of a muramyl dipeptide on human blood leukocyte functions and their membrane antigens. Cell Immunol 134:1-10.
29. 29. Dinarello CA, Thompson RC (1991) Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 12:404-410.
30. 30. Arend WP, Smith JR. MF, Janson RW, Joslin FG (1991) IL-1 receptor antagonist and IL-1β production in human monocytes are regulated differently. J Immunol 147:1530-1536.
31. 31. DeForge LE, Tracey DE, Kenney JS, Remick DG (1992) Interleukin-1 receptor antagonist protein inhibits interleukin-8 expression in lipopolysaccharide-stimulated human whole blood. Am J Pathol 140:1045-1054.
32. 32. Imeri L, Opp MR, Krueger JM ( 1993) An IL-1 receptor and an IL-1 receptor antagonist attenuate muramyl dipeptide- and IL-1-induced sleep and fever. Am J Physiol 265:R907-R913.
33. 33. Riveau G, Chedid L (1987) Comparison of immuno- and neuropharmacological activities of MDP and Murabutide. In J.A. Majde (ed.) Immunopharmacology of Infectious Diseases: Vaccine Adjuvants and Modulators of Non Specific Resistance. Alan R. Liss, Inc., New York. pp 213-222.
34. 34. Eisenberg SP, Brewer MT, Verderber E, Heimdal PL, Brandhuber BJ, Thompson RC (1991) IL-1 receptor antagonist (IL-1Ra) is a member of the IL-1 gene family = evolution of a cytokine control mechanism. Proc Natl Acad Sci USA 88:5232-5236.
35. 35. Janson RW, Hance KR, Arend WP (1991) Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor. J Immunol 147:4218-4223.
36. 36. Tilg J, Mier JW, Vogel W, Aulitzky WE, Wiedermann CJ, Vannier E, Huber C, Dinarello CA (1993) Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 150:4687-4692.
37. 37. Trinchieri G (1993) Interleukin-12 and its role in the generation of Th1 cells. Immunol Today 14:335-338.
38. 38. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, Young HA, Wolf SF, Young D, Clark SC, Trinchieri G (1991) Induction of Interferon γ production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173:869-879.
39. 39. Wahl SM, McCartney-Francis N, Hunt DA, Smith PD, Wahl LM, Katona IM (1987) Monocyte interleukin 2 receptor gene expression and interleukin 2 augmentation of microbicidal activity. J Immunol 139:1342-1347.
40. 40. Suzuki K, Torii K, Hida S, Hayashi H, Hiyama Y, Oomoto Y, Takii T, Chiba T, Onozaki K (1994) Differences in interleukin 1 (IL-1), IL-6, tumor necrosis factor and IL-1 receptor antagonist production by human monocytes stimulated with muramyl dipeptide (MDP) and its stearoyl derivative, romurtide. Immunopharmacology 28:31-38.
41. 41. Kasahara K, Strieter RM, Standiford TJ, Kunkel SL (1993) Adherence in combination with lipopolysaccharide, tumor necrosis factor or interleukin-1β; potentiates the induction of monocyte-derived interleukin-8. Pathobiology 61:57-66.
42. 42. Darcissac ECA, Bahr GM, Parant MA, Chedid LA, Riveau GJ (1966) Selective induction of CD 11a,b,c/CD 18 and CD54 expression at the cell surface of human leukocytes by muramyl peptides. Cell Immunol 169:294-301.
43. 43. Chujor CSN, Kuhn B, Schewerer B, Bernheimer H, Lewis WR, Bevec D (1992) Specific inhibition of mRNA accumulation for lymphokines in human T-cell line Jurkat by mycobacterial lipoarabinomannan antigen. Clin Exp Immun 87:398-403.
44. 44. Collins M, Hunsaker RW (1985) Improved hybridization assays employing tailed oligonucleotide probes and nick-translated plasmid probes. Anal Biochem 150:218-224.